A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

Bernadette Jeremiasse; Ravian L. van Ineveld; Veerle Bok; Michiel Kleinnijenhuis; Sam de Blank; Maria Alieva; Hannah R. Johnson; Esmee J. van Vliet; Amber L. Zeeman; Lianne M. Wellens; Gerard Llibre-Palomar; Mario Barrera Roman; Alessia Di Maggio; Johanna F. Dekkers; Sabrina Oliveira; Alexander L. Vahrmeijer; Jan J. Molenaar; Marc H. W. A. Wijnen; Alida F. W. van der Steeg; Ellen J. Wehrens; Anne C. Rios

doi:10.1038/s44321-024-00084-4

A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

Bernadette Jeremiasse, Ravian L. van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R. Johnson, Esmee J. van Vliet, Amber L. Zeeman, Lianne M. Wellens, Gerard Llibre-Palomar, Mario Barrera Roman, Alessia Di Maggio, Johanna F. Dekkers, Sabrina Oliveira, Alexander L. Vahrmeijer, Jan J. Molenaar, Marc H. W. A. Wijnen, Alida F. W. van der Steeg, Ellen J. WehrensAnne C. Rios^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.

Original language	English
Pages (from-to)	1495-1514
Number of pages	20
Journal	EMBO Molecular Medicine
Volume	16
Issue number	7
Early online date	Jun 2024
DOIs	https://doi.org/10.1038/s44321-024-00084-4
Publication status	Published - Jul 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Funding

We thank the Princess Ma\u0301xima Center for Pediatric Oncology for technical support and the Hubrecht Institute and Zeiss for imaging support and collaboration. All imaging was performed at the Princess Ma\u0301xima Imaging Center. We thank the HUB for providing BC PDOs, the Princess Ma\u0301xima Center Organoid Facility for organoid culture support, and J. Drost and J. B\u00FChl (Princess Ma\u0301xima Center for Pediatric Oncology) for providing healthy kidney organoid lines. We also thank the R2 Genomics Analysis and Visualization Platform ( http://r2.amc.nl ), and J. Koster and R. Volckmann in particular, for RNA database availability and analyses support, Elthera for providing L1CAM antibodies, and QVQ for supplying NCAM1 nanobodies. We thank E. Bokobza and M. Buchholz for providing the healthy breast organoid lines and members of the Dream3D (Rios group) for offering critical feedback on the project and manuscript. This work was financially supported by the Princess Ma\u0301xima Center for Pediatric Oncology, Oncode Institute, the Netherlands, and the Dutch Neuroblastoma Foundation (Villa Joep). ACR was supported by an European Research Council (ERC)-starting grant 2018 project (no. 804412).

Funders	Funder number
Oncode Institute
Prinses Máxima Centrum voor kinderoncologie
Dutch Neuroblastoma Foundation
European Research Council	804412

Keywords

Breast Cancer
Fluorescence-guided Surgery
Multi-spectral 3D Imaging
Neuroblastoma
Patient-derived Organoids

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s44321-024-00084-4Licence: CC BY

jeremiasse-et-al-2024-a-multispectral-3d-live-organoid-imaging-platform-to-screen-probes-for-fluorescence-guided-surgeryFinal published version, 7.03 MBLicence: CC BY

Cite this

Jeremiasse, B., van Ineveld, R. L., Bok, V., Kleinnijenhuis, M., de Blank, S., Alieva, M., Johnson, H. R., van Vliet, E. J., Zeeman, A. L., Wellens, L. M., Llibre-Palomar, G., Barrera Roman, M., Di Maggio, A., Dekkers, J. F., Oliveira, S., Vahrmeijer, A. L., Molenaar, J. J., Wijnen, M. H. W. A., van der Steeg, A. F. W., ... Rios, A. C. (2024). A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery. EMBO Molecular Medicine, 16(7), 1495-1514. https://doi.org/10.1038/s44321-024-00084-4

@article{8248d8804af748f69af2cee2c17bcaf9,

title = "A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery",

abstract = "Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.",

keywords = "Breast Cancer, Fluorescence-guided Surgery, Multi-spectral 3D Imaging, Neuroblastoma, Patient-derived Organoids",

author = "Bernadette Jeremiasse and {van Ineveld}, {Ravian L.} and Veerle Bok and Michiel Kleinnijenhuis and {de Blank}, Sam and Maria Alieva and Johnson, {Hannah R.} and {van Vliet}, {Esmee J.} and Zeeman, {Amber L.} and Wellens, {Lianne M.} and Gerard Llibre-Palomar and {Barrera Roman}, Mario and {Di Maggio}, Alessia and Dekkers, {Johanna F.} and Sabrina Oliveira and Vahrmeijer, {Alexander L.} and Molenaar, {Jan J.} and Wijnen, {Marc H. W. A.} and {van der Steeg}, {Alida F. W.} and Wehrens, {Ellen J.} and Rios, {Anne C.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = jul,

doi = "10.1038/s44321-024-00084-4",

language = "English",

volume = "16",

pages = "1495--1514",

journal = "EMBO Molecular Medicine",

issn = "1757-4676",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "7",

}

Jeremiasse, B, van Ineveld, RL, Bok, V, Kleinnijenhuis, M, de Blank, S, Alieva, M, Johnson, HR, van Vliet, EJ, Zeeman, AL, Wellens, LM, Llibre-Palomar, G, Barrera Roman, M, Di Maggio, A, Dekkers, JF, Oliveira, S, Vahrmeijer, AL, Molenaar, JJ, Wijnen, MHWA, van der Steeg, AFW, Wehrens, EJ & Rios, AC 2024, 'A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery', EMBO Molecular Medicine, vol. 16, no. 7, pp. 1495-1514. https://doi.org/10.1038/s44321-024-00084-4

TY - JOUR

T1 - A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

AU - Jeremiasse, Bernadette

AU - van Ineveld, Ravian L.

AU - Bok, Veerle

AU - Kleinnijenhuis, Michiel

AU - de Blank, Sam

AU - Alieva, Maria

AU - Johnson, Hannah R.

AU - van Vliet, Esmee J.

AU - Zeeman, Amber L.

AU - Wellens, Lianne M.

AU - Llibre-Palomar, Gerard

AU - Barrera Roman, Mario

AU - Di Maggio, Alessia

AU - Dekkers, Johanna F.

AU - Oliveira, Sabrina

AU - Vahrmeijer, Alexander L.

AU - Molenaar, Jan J.

AU - Wijnen, Marc H. W. A.

AU - van der Steeg, Alida F. W.

AU - Wehrens, Ellen J.

AU - Rios, Anne C.

PY - 2024/7

Y1 - 2024/7

N2 - Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.

AB - Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.

KW - Breast Cancer

KW - Fluorescence-guided Surgery

KW - Multi-spectral 3D Imaging

KW - Neuroblastoma

KW - Patient-derived Organoids

UR - http://www.scopus.com/inward/record.url?scp=85195517233&partnerID=8YFLogxK

U2 - 10.1038/s44321-024-00084-4

DO - 10.1038/s44321-024-00084-4

M3 - Article

C2 - 38831131

SN - 1757-4676

VL - 16

SP - 1495

EP - 1514

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

IS - 7

ER -

A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this